President Barack Obama's proposed $3.7 trillion budget could do what legislators, the courts and the Federal Trade Commission have been unable to do on their own: bring lower-cost generic drugs to market faster.
But don’t bet on it. Those items in the Obama budget are likely to be bargaining chips in the upcoming (can you say “contentious”?) budget debate. Consumers really don’t have a seat at that table; the biopharmaceutical industry does.